Trial Profile
Prostate Cancer Antigen-3 (PCA-3) and TMPRSS2-ERG (T2-ERG) Score Changes During Initiation of Androgen Deprivation Therapy (ADT) With Triptorelin 22.5mg in Patients With Advanced Prostate Cancer (PCA): A Phase III, Single Arm Multicentre Study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Triptorelin (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- Acronyms Triptocare; Triptocare-LT
- Sponsors Ipsen
- 29 Oct 2013 Planned patient number of the extension trial changed from 315 to 187 according to the ClincalTrials.gov record.
- 29 Oct 2013 Planned patient number of the extension trial changed from 315 to 187 according to the ClincalTrials.gov record.
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (Parent trial: NCT01020448).